SecBot SecBot
8-K ·Filed Nov 5, 2026

CRBU

Caribou Biosciences, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed11d 11h ago SEC0001619856-26-000060
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The strategic alternatives process is open-ended with no timeline. Watch for any definitive agreement, asset sale, or dissolution plan. The cash runway of $94.8M provides some time but the company has no ongoing clinical programs and minimal revenue.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

CRBU drug pipeline →

CB-011

▼ Bearish Named in this 8-K
Impact
Phase
Phase 1 (discontinued)
Time to market
Not applicable. CB-011 development has been discontinued and the program terminated (Oct 2026).
Next catalyst
None dated

What to watchCB-011 development has been discontinued. The next event is the ASH 2026 presentation (Dec 12-15), but it is a look-back on a terminated program. The real stock-moving catalyst is the strategic alternatives process (potential sale/merger of Caribou), which has no announced timeline. Watch for any acquisition or asset-sale announcement from the company's exploration process.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.4487
T+0 close · Nov 5, 2026 · via day close
Latest settled
−19.34%
T+5 · $0.3619 · next T+20 in 20d
Vs SPY
−21.94%
α at T+5
Latest observation
−19.39%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $0.4487entry
  2. T+1 · 8d ago −6.44%α −8.81% · $0.4198
  3. T+5 · 4d ago −19.34%α −21.94% · $0.3619
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Caribou Biosciences reported Q3 2026 revenue of $1.6M (below $2.2M a year ago) and a GAAP net loss of $26.6M ($0.25 per share). The filing confirms the October 6 restructuring that discontinues both clinical programs (vispa-cel and CB-011) and launches a strategic alternatives process that may include dissolution and liquidation. The company has $94.8M in cash, down from $142.8M at year-end 2025.

Key Financial Metrics

EPS
−$0.25
est −$0.26 · +3.9%
Revenue
$1.6M
est $1.6M · +0.4% · -26.9% YoY
Rating
beat

Key Facts

  • Q3 2026 licensing revenue $1.6M vs $2.2M a year ago
  • GAAP net loss $26.6M ($0.25 per share) vs $27.5M ($0.30) a year ago
  • Cash and marketable securities $94.8M as of Sep 30, 2026, down from $142.8M at Dec 31, 2025
  • Board approved restructuring on Oct 6, 2026, discontinuing vispa-cel and CB-011 clinical trials
  • Company is exploring strategic alternatives including merger, acquisition, business combination, or dissolution and liquidation
  • Impairment charges of $12.15M and impairment of equity investment of $9.158M recorded in Q3 2026
  • Market cap $49M with normal daily move of 12.6%

Financial Impact

Cash burn of ~$48M in nine months; $94.8M remaining; restructuring eliminates R&D spend on two clinical programs

revenuecashnet lossimpairment charges

Risk Factors

  • No timeline for strategic alternatives process; outcome uncertain
  • Potential dissolution and liquidation with uncertain recovery for equity holders
  • No ongoing clinical programs; revenue from licensing is minimal and declining
  • Impairment charges of $21.3M in Q3 2026 reflect asset write-downs

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001619856-26-000060
Document: crbu-20261105.htm0001619856-26-000060
Document: 0001619856-26-000060-index-headers.html0001619856-26-000060
Document: 0001619856-26-000060-index.html0001619856-26-000060
Document: 0001619856-26-000060.txt0001619856-26-000060
8-K Data (Synthetic)0001619856-26-000060

Track record

13 reports on CRBU

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 7/10 Viewing Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
  2. Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
  3. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
  4. Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  5. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  6. Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
  8. Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  9. Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  10. Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026